Observational studyFuture oncology (London, England)2019
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
Observational study in Future oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care.European journal of haematology · 2026Review
- Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias.Current hematologic malignancy reports · 2026Review
- Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis.European journal of haematology · 2026Observational
- Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.Clinical hematology international · 2026Article
- Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020.Cancer medicine · 2025Article
- Multi-omics machine learning identifies diagnostic gene signatures and functionally supports PRKACB involvement in macrophage inflammatory responses in sepsis.Frontiers in immunology · 2025Article
- The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).BMC medical research methodology · 2024Article
- A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.Annals of hematology · 2024Observational
- The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge.Clinical hematology international · 2024Article
- Article
- Article
- Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland.EJHaem · 2023Article
- The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research.The oncologist · 2023Article
- Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective.Clinical hematology international · 2022Review
- Article
- Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.Frontiers in oncology · 2022Review
- Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS).Annals of hematology · 2021Observational
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients' outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.